Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
出版年份 2020 全文链接
标题
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
作者
关键词
-
出版物
Blood Advances
Volume 4, Issue 9, Pages 1894-1905
出版商
American Society of Hematology
发表日期
2020-05-08
DOI
10.1182/bloodadvances.2020001503
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells
- (2019) Ines Ugele et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
- (2018) Lukas Bunse et al. NATURE MEDICINE
- Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
- (2018) Lynn Quek et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
- (2018) Janeta Popovici-Muller et al. ACS Medicinal Chemistry Letters
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
- (2018) James J. Harding et al. Cancer Discovery
- Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
- (2017) Gary Kohanbash et al. JOURNAL OF CLINICAL INVESTIGATION
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced
- (2017) Huixia Zhu et al. PLoS One
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells
- (2016) Stuart Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies
- (2016) Michael J. Kluk et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
- (2016) Mélissa Carbonneau et al. Nature Communications
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
- (2015) Courtney D. DiNardo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
- (2015) R J Molenaar et al. LEUKEMIA
- Insulator dysfunction and oncogene activation in IDH mutant gliomas
- (2015) William A. Flavahan et al. NATURE
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
- (2014) Supriya K. Saha et al. NATURE
- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
- (2012) A. Sexauer et al. BLOOD
- Potential application ofIDH1andIDH2mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis
- (2012) Kuang-Guo Zhou et al. LEUKEMIA & LYMPHOMA
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of D-, L-2-hydroxyglutarate and 3-hydroxyglutarate into neurons
- (2011) Katja Brauburger et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Acute Myeloid Leukemia WithIDH1orIDH2Mutation
- (2010) Keyur P. Patel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started